The availability of an anticoagulant reversal agent in Australia has changed the conversation about treatment choices for patients and removed a concern for clinicians, an expert says. Speaking to the limbic following a breakfast symposium sponsored by Boehringer Ingelheim at the recent Cardiac Society for Australia and New Zealand’s annual congress Professor John Amerena a ...
How an anticoagulant reversal agent is changing the treatment conversation
8 Sep 2016
Sponsored by Boehringer Ingelheim Pty Ltd